Quotables
"Flight by machines heavier than air is unpractical and insignificant, if not utterly impossible."
Simon Newcomb, astronomer ; Said in 1902, less than two years before the first flight at Kitty Hawk
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| 7098193 | Compositions comprising a defined polysaccharide component The present disclosure provides compositions comprising an extracted portion of psyllium seed in combination with one or more of a binder, suspending agent, or edible acid. In particular, the present invention is directed to compositions comprising: ... | 08/29/2006 |
| 7026303 | Compositions comprising a polysaccharide component and one or more coating layers The present disclosure provides compositions comprising a plurality of agglomerates comprising a polysaccharide component comprising xylose and arabinose, wherein the ratio of xylose to arabinose is at least about 3:1, by weight; wherein the compositions further com... | 04/11/2006 |
| 6982254 | Compositions comprising a plurality of particles or agglomerates having a defined particle size The present disclosure provides compositions comprising an extracted portion of psyllium seed in combination with one or more of a binder or edible acid. In particular, the present invention is directed to compositions comprising a polysaccharide component comprisin... | 01/03/2006 |
| 6890568 | Method for management of blood glucose levels A composition for managing blood glucose levels is herein described. The composition comprises decocted tea and vanadate and does not cause the same side effects as vanadate and water mixtures known in the prior art. Specifically, the vanadate suspended in decocted ... | 05/10/2005 |
| 6797283 | Gastric retention dosage form having multiple layers The present invention is directed to a multilayered dosage form which is adapted for retention in the stomach and useful for the prolonged delivery of an active agent to a fluid environment of use. The active agent dosage form is a multilayer core, often bilayer, fo... | 09/28/2004 |
| 6770635 | Method for medicating the inflammatory controlling system and adverse inflammatory reactions and for making compounds for treating the pathology of adverse inflammatory reactions Adverse inflammatory reactions can be treated by administrating to an organism a composition having diglucosylamine as the active ingredient. The preferred compound is di-Beta-D-glucopyranosylamine. A simple method for making diglucosylamine in high purity is obtain... | 08/03/2004 |
| 6663874 | Composition to alleviate pain and topical method of applying same A composition for use by animals, including humans, to alleviate pain and/or inflammation around a painful joint, joint replacement surgery site, muscle, tendon, and/or ligament. A method to ameliorate pain and/or inflammation in or around a joint, muscle... | 12/16/2003 |
| 6635655 | Therapeutic uses of di-aryl acid derivatives The use of diaryl acid derivatives of formula (I) ##STR1## or pharmaceutically acceptable salts, N-oxides, hydrates or solvates thereof, wherein the variables shown are defined in the disclosure, and their pharmaceutical compositions as PPAR ligand recept... | 10/21/2003 |
| 6573291 | Method and use The invention relates to a method of antagonizing GLP-1 activity in a mammalian patient, comprising administering to said patient an effective amount of a compound of the general formula I: ##STR1## wherein R1 and R2 independently of... | 06/03/2003 |
| 6410511 | Formulations for amylin agonist peptides The present invention is concerned with a pharmaceutical formulation in a container, for example, a vial, prefilled cartridge, prefilled syringe or disposable pen, comprising approximately 0.01 to about 0.5% (w/v) amylin agonist, preferably pramlintide, i... | 06/25/2002 |
| 6376512 | Therapeutic uses of quinoline derivatives A method for mediating the activity of PPAR-γ receptor comprising contacting said PPAR-γ receptor with a compound of formula I defined herein. Also disclosed is the treatment of a patient suffering from a physiological disorder capable of being modulate... | 04/23/2002 |
| 6048514 | Amylin activity assays Novel methods for use in identifying or assaying compounds which can simulate the ability of amylin to cause hyperlactemia and hyperglycemia in in vivo biological models, or for use in evaluating the potency of compounds known or suspected to simulate the... | 04/11/2000 |
| 5925647 | Methods for use of cryptolepine analogs with hypoglycemic activity Novel cryptolepine analogs useful as hypoglycemic agents and methods for their use as hypoglycemic agents, for example, in the treatment of diabetes, and a method for their synthesis are described. As hypoglycemic agents, the novel cryptolepine analogs ar... | 07/20/1999 |
| 5888993 | Vanadium compounds in the treatment of elevated blood sugar levels There are provided vanadium compositions for use in the treatment of hypertension, obesity and diabetes, in particular improved oral compositions comprising oxovanadium (IV) chelates of monoprotic, bidentate oxygen, oxygen and oxygen, nitrogen coordinatin... | 03/30/1999 |
| 5866563 | Vanadium compositions There are provided vanadium compositions for use in the treatment of hypertension, obesity and diabetes, in particular improved oral compositions comprising oxovanadium (IV) chelates of monoprotic, bidentate oxygen, oxygen and oxygen, nitrogen coordinatin... | 02/02/1999 |
| 5846544 | Composition and method for reducing blood sugar levels in diabetic humans The present invention concerns a method and composition for reducing blood sugar levels in diabetic human subjects. Practice of the invention requires ingestion of bilberry fruit and valerian root in timed relation to meals. Neither bilberry fruit nor val... | 12/08/1998 |
| 5837255 | Method of reducing blood glucose by administering Harunganin or Vismin The use of extracts from Harungana or Vismia spp. or anthracenone compounds harunganin and vismin contained therein or isolated therefrom as hypoglycemic agents, as well as methods for obtaining the hypoglycemic agents are described. According to a prefer... | 11/17/1998 |
| 5773004 | Compositions for curing diabetes mellitus, processes for the preparation of same, and usage of same Disclosed is the composition for treating or curing diabetes mellitus containing an ingredient or component suitable for treatment of diabetes mellitus from an extract obtained by immersing a plant belonging to genus Tithonia and/or Ludwigia in a pharmaco... | 06/30/1998 |
| 5760047 | Method for treatment of obesity using prolactin modulators and diet The present invention is directed to an improvement in a method of weight and/or body-fat reduction comprising a (preferably moderate) reduction in the caloric intake of a subject in need of such treatment in combination with administration to said subjec... | 06/02/1998 |
| 5635529 | Sulfonamidodioxepanes, methods of preparation, intermediates, salts and use thereof Novel O-substituted or O-unsubstituted 6-sulfonamido-1,3-dioxepane-5-ols having hypoglycemic activity are obtained from 6-amino-1,3-dioxepane-5-ol, tetrahydro-6H-[1,3]-dioxepino[5,6-d]oxazole, 5,6-epoxy-1,3-dioxepane or N-sulfonyl-tetrahydro-1H,4H-[1,3]-d... | 06/03/1997 |
| 5631245 | Method for medicating the inflammatory controlling system and adverse inflammatory reactions and for making compounds for treating the pathology of adverse inflammatory reactions Adverse inflammatory reactions can be treated by administrating to an organism a composition having diglucosylamine as the active ingredient. The preferred compound is di-Beta-D-glucopyranosylamine. A simple method for making diglucosylamine in high purit... | 05/20/1997 |
| 5629319 | Hypoglycemic agent from cryptolepis The use of extracts from Cryptolepis sp. or quindoline alkaloids such quindoline and cryptolepine contained therein as hypoglycemic agents, as well as methods for obtaining the hypoglycemic agents are described. According to a preferred embodiment, the ex... | 05/13/1997 |
| 5594005 | Use of quinoline-3-carboxamide compounds for treatment of diabetes Quinoline-3-carboxamide compounds of formula (I) are effective in preventing, treating or ameliorating Type I diabetes. ##STR1## wherein ----- represents two conjugated double bonds between the atoms comprised by the dashed line, X1 and X | 01/14/1997 |
| 5576306 | Pharmaceutical compositions and uses of water-soluble, high-viscosity grade cellulose ethers Water-soluble, high-viscosity grade cellulose ether compositions are useful for the reduction of serum lipid levels, particularly total serum cholesterol, serum triglycerides, and low-density lipoprotein (LDL) levels and/or attenuate the postprandial rise... | 11/19/1996 |
| 5569655 | Substituted heterocyclylisoquinolinium salts and compositions and method of use thereof Substitutued heterocyclylisoquinolinium salts, pharmaceutical compositions containing them and methods for the treatment or prevention of neurodegenerative disorders or neurotoxic injuries utilizing them.... | 10/29/1996 |
| 5527790 | Bis(maltolato)oxovanadium compositions for the treatment of elevated blood sugar There are provided vanadium compositions for use in the treatment of hypertension, obesity and diabetes, in particular improved oral compositions comprising oxovanadium (IV) chelates of monoprotic, bidentate oxygen, oxygen and oxygen, nitrogen coordinatin... | 06/18/1996 |
| 5512296 | Methods for inhibiting neuronal damage A method for inhibiting neuronal damage due to hypoglycemia comprising administering to a human in need thereof an effective amount of a compound having the formula ##STR1## wherein R1 and R3 are independently hydrogen, --CH | 04/30/1996 |
| 5356879 | D-tagatose as anti-hyperglycemic agent This invention discloses the usefulness of D-tagatose as a treatment for hyperglycemia, diabetes mellitus, and the inhibition of formation of advanced glycosylation end-products associated with the aging process. This invention discloses edible formulations an... | 10/18/1994 |
| 5300496 | Complexed vanadium for the treatment of diabetes mellitus A pharmaceutical composition useful for lowering blood sugar and suppressing appetite in mammals. The composition comprises compounds of a formula selected from VOL2 or VO(OR)L2 in which L is a bidentate monoprotic ligand and R is an... | 04/05/1994 |
| 5281584 | Effect of particle-size distribution of cellulose ethers on palatability of compositions The present invention is directed to a baked food composition comprising food ingredients and a water-soluble cellulose ether which is useful for reducing the low-density lipoprotein serum cholesterol level of an animal. Use of a specific particle-size di... | 01/25/1994 |
| 5190916 | Use of ovomacroglobulin as an agent for treating wound and inflammation A treating agent such as a wound therapeutic agent, inflammation therapeutic agent, hair growth agent and hair tonic, and a cosmetic, comprising as an effective component ovomacroglobulin are disclosed. They can act on the skin, a scalp or hairs to exhibi... | 03/02/1993 |
| 5183823 | Pyridine N-oxide compounds which are useful as hypoglycemic and hypolipidemic agents There is disclosed a novel thiazolidinedione derivative of the general formula (I): ##STR1## wherein R1 and R2 are the same or different and are a hydrogen atom or a lower alkyl group, or a salt thereof. The thiazolidinedione ... | 02/02/1993 |
| 5179079 | Nasal formulation and intranasal administration therewith The systemic absorption after intranasal administration of certain drugs, in particular pharmacologically active polypeptides is enhanced in the presence of a phospholipid, such as a phosphatidylcholine (a lecithin), preferably admixed with a vegetable oi... | 01/12/1993 |
| 5141927 | Antihypertensive preparation comprising an alginate and vitamin D Alginates capable of binding sodium and having ion exchanging capacity are used in conjunction with vitamin D for the treatment of hypertension. Such alginates may be acid extracted from seaweeds such as Asophylum nodosum. The acid-extracted alginate may ... | 08/25/1992 |
| 5110595 | Implant preparations containing bioactive macromolecule for sustained delivery Implant preparations capable of sustained action when inserted are comprised of powder of a natural lipoidal substance in thorough admixture with bioactive macromolecule, followed by compression under pressure into a disc or rod that can be broken and use... | 05/05/1992 |
| 5091524 | Glycosidase inhibitor salbostatin, process for its preparation, and its use Salbostatin, a compound of the formula I ##STR1## acts as a glycosidase inhibitor and is suitable for use in pharmacy and in plant protection.... | 02/25/1992 |
| 5008248 | Veterinary compositions for the treatment of scours and dehydration A veterinary composition comprising 75-85% of an actively absorbed monosaccharide, from 3.5 to less than 5% of an actively absorbed naturally occurring amino acid, 5-10% of one or more citrate salts. The composition is useful in the treatment of diarrhoea... | 04/16/1991 |
| 4985439 | Glucose tolerance factor and method of making same A glucose tolerance factor which reduces blood sugar in mammals and is derived from yeast. The glucose tolerance factor can be isolated from autolyzed brewer's yeast extract by sequential fractionation on Sephadex G-75, Biogel P-6, Biogel P-2, to give a p... | 01/15/1991 |
| 4968790 | Antidiabetic phosphates Phosphates are disclosed which stimulate the enzyme fructose-1,6-bisphosphatase and inhibit the enzyme 6-phosphofructo-1-kinase, thereby lowering glucose levels in mammals. These phosphates may thus be used to treat hyperglycemia and/or diabetes. Pro... | 11/06/1990 |
| 4918099 | Drug, preparation and use thereof A novel drug comprises as active ingredient an extract extractable from plant material of plants belonging to the genus Caesalpinia, one or several components of this extract and/or one or several substances present in this extract or derived therefrom bu... | 04/17/1990 |
